A compound which is of formula: or is a pharmaceutically acceptable salt, hydrate, solvate, or rotamer thereof, wherein A is selected from the group consisting of -CO 2 H, -SO 3 H, -PO 3 H 2 and a tetrazole; ring vertices a, b, c and d are independently selected from CH and C(R 1); each R 1 is independently selected from the group consisting of halogen, CN, -SF 5, C 1-8 alkyl, C 3-8 cycloalkyl, C 2-8 alkenyl, C 2-8 alkynyl, C 1-8 haloalkyl, -OR a, -SR a, -COR a, -NR a R b, and 5- or 6-membered heteroaryl, wherein the alkyl portions of R 1 are optionally further substituted with 1-3 R a; and optionally, adjacent R 1 members are connected to form an additional 5- or 6-membered ring which is saturated or unsaturated having ring vertices selected from C, O, S and N, wherein the additional 5- or 6-membered ring is optionally substituted with one or two members selected from the group consisting of halogen, hydroxyl, C 1-4 alkyl, C 1-4 alkoxy and C 1-4 haloalkyl; the subscript m is an integer of from 0 to 2; the subscript n is an integer of from 0 to 3; each R 2 and R 3 is independently selected from the group consisting of halogen, CN, C 1-8 alkyl, C 3-8 cycloalkyl, C 2-8 alkenyl, C 2-8 alkynyl, C 1-8 haloalkyl, aryl, -OR a, -NR a R b and -N(R a)-C 1 -C 4 alkylene-OR b, and wherein the alkyl or aryl portions of R 2 and R 3 are optionally further substituted with 1-3 R a; Ar is a 6-membered aromatic or heteroaromatic ring selected from the group consisting of benzene, pyridine, and pyrimidine that is optionally substituted with from 1 to 3 R 4 substituents independently selected from the group consisting of halogen, CN, -SF 5, C 1-8 alkyl, C 3-8 cycloalkyl, C 2-8 alkenyl, C 2-8 alkynyl, C 1-8 haloalkyl, C 1-8 hydroxyalkyl, -OR a, -NR a R b, 5- or 6-membered heteroaryl, and 3-, 4-, 5- or 6-membered heterocycloalkane wherein the heteroatoms present as ring vertices of the heteroaryl and heterocycloalkane rings are selected from N, O and S, and wherein the alkyl, cycloalkyl, aryl, heteroaryl and hetereocycloalkane portions of R 4 are optionally further substituted with 1-3 R a; each R a and R b is independently selected from the group consisting of hydrogen, hydroxyl, halogen, cyano, C 1-4 alkyl, C 1-4 alkoxy, C 1-4 halo alkyl, C 3-6 cycloalkyl, amino, C 1-8 alkylamino, and di C 1-8 alkylamino, or when attached to a nitrogen atom are optionally combined to form a 4- to 7-membered saturated ring, which is optionally substituted with oxo; wherein each cycloalkyl refers to a monocyclic, bicyclic, or polycyclic hydrocarbon ring having no more than one double bond between the ring vertices. A is selected from the group consisting of -CO 2 H, -SO 3 H, -PO 3 H 2 and a tetrazole; ring vertices a, b, c and d are independently selected from CH and C(R 1); each R 1 is independently selected from the group consisting of halogen, CN, -SF 5, C 1-8 alkyl, C 3-8 cycloalkyl, C 2-8 alkenyl, C 2-8 alkynyl, C 1-8 haloalkyl, -OR a, -SR a, -COR a, -NR a R b, and 5- or 6-membered heteroaryl, wherein the alkyl portions of R 1 are optionally further substituted with 1-3 R a; and optionally, adjacent R 1 members are connected to form an additional 5- or 6-membered ring which is saturated or unsaturated having ring vertices selected from C, O, S and N, wherein the additional 5- or 6-membered ring is optionally substituted with one or two members selected from the group consisting of halogen, hydroxyl, C 1-4 alkyl, C 1-4 alkoxy and C 1-4 haloalkyl; the subscript m is an integer of from 0 to 2; the subscript n is an integer of from 0 to 3; each R 2 and R 3 is independently selected from the group consisting of halogen, CN, C 1-8 alkyl, C 3-8 cycloalkyl, C 2-8 alkenyl, C 2-8 alkynyl, C 1-8 haloalkyl, aryl, -OR a, -NR a R b and -N(R a)-C 1 -C 4 alkylene-OR b, and wherein the alkyl or aryl portions of R 2 and R 3 are optionally further substituted with 1-3 R a; Ar is a 6-membered aromatic or heteroaromatic ring selected from the group consisting of benzene, pyridine, and pyrimidine that is optionally substituted with from 1 to 3 R 4 substituents independently selected from the group consisting of halogen, CN, -SF 5, C 1-8 alkyl, C 3-8 cycloalkyl, C 2-8 alkenyl, C 2-8 alkynyl, C 1-8 haloalkyl, C 1-8 hydroxyalkyl, -OR a, -NR a R b, 5- or 6-membered heteroaryl, and 3-, 4-, 5- or 6-membered heterocycloalkane wherein the heteroatoms present as ring vertices of the heteroaryl and heterocycloalkane rings are selected from N, O and S, and wherein the alkyl, cycloalkyl, aryl, heteroaryl and hetereocycloalkane portions of R 4 are optionally further substituted with 1-3 R a; each R a and R b is independently selected from the group consisting of hydrogen, hydroxyl, halogen, cyano, C 1-4 alkyl, C 1-4 alkoxy, C 1-4 halo alkyl, C 3-6 cycloalkyl, amino, C 1-8 alkylamino, and di C 1-8 alkylamino, or when attached to a nitrogen atom are optionally combined to form a 4- to 7-membered saturated ring, which is optionally substituted with oxo; wherein each cycloalkyl refers to a monocyclic, bicyclic, or polycyclic hydrocarbon ring having no more than one double bond between the ring vertices.